ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Green Cross Lab Cell (144510.KQ)
Green Cross Lab Cell stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · KOSDAQ · South Korea
₩12,950▼ -0.08%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Green Cross Lab Cell in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Green Cross Lab Cell
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Green Cross Lab Cell a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩11,891 and ₩14,003; in 9 out of 10, between ₩10,287 and ₩16,186. Estimated annual volatility is 47%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩190B
- Market cap (USD)
- $143M
- 52-week high
- ₩28,450
- 52-week low
- ₩11,610
- Revenue (12 months)
- ₩162B
- Gross margin
- 18.1%
- Operating margin
- -2.4%
- Net margin
- -152.1%
- Beta
- 0.57
What this means
ATLAS does not publish a fair value for 144510.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 144510.KQ has traded between ₩11,610 and ₩28,450. Today it is 54.5% below that high and 12% above its low.
Its beta is 0.57: it tends to move less than the market.
About the company
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC.
Want to see everything about Green Cross Lab Cell?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Green Cross Lab Cell do?
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC.
What is the chance 144510.KQ goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, 144510.KQ ends the month between ₩11,891 and ₩14,003.
How big is Green Cross Lab Cell and what is its P/E ratio?
Green Cross Lab Cell's market capitalization is ₩190B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 144510.KQ?
ATLAS estimates annual volatility at 47%. In a typical month, half of the outcomes end between ₩11,891 and ₩14,003.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer